Allo-SCT from an HLA related or unrelated donor is the first line treatment for newly diagnosed patients with BMFS younger than 40 years, and for older patients that failed immunosuppressive therapy. Cohort retrospective analysis of BMFS patients receiving Allo-SCT in a mixed (pediatric-adult) transplant center in Bogota, Colombia, are reported. Log-rank tests(Lrt) analyses were used to determine the effects of age, conditioning regimen and year of treatment on survival. Between January 1993 and August 2011, 74 transplants were performed in 70 patients(52 acquired SAA,16 Fanconi Anemia and 2 pure red cell aplasia). Table 1 reflects patients and transplant characteristics. 70 grafts were obtained from HLA identical siblings, 3 from unrelated CBU and 1 from a haploidentical sibling. Conditioning regimens used were: RIC Cy-Flu-ATG(22), Cy-ATG(33) and Cy(12). 4 patients were conditioned with Campath containing regimens and 3 with other. Before 2004 most patients received Cs and MTX as GVHD prophylaxis, after 2004 Cs and MMF was used in the majority.Table 1Patients and transplant characteristicsGender, n M/F42/28Age, years mean (range)25.5 (4 - 60)Time from diagnosis to transplant, months mean (range)26.4 (2.1 - 143)More than 10 transfusions before transplant, n Y/N41/26 (3 not known)Stem cell source n (BM/PBSC/CBU)6/65/3Hospital stay, days mean (range)29.9 (16-94)CD34+ x 10-6 infused mean (range)3.7 (0.3-17)∗Excluding CBUTPMN graft, days mean (range)11.5 (7-21)∗∗ Excluding CBUT Open table in a new tab One 13 year old patient, expired before stem cell infusion due to sepsis. For the first transplant 68 patients engrafted, average at 11.5 days without significant differences between conditioning regimens. 3 patients (1 Cy-ATG, 1 Campath based, 1 Cy-Flu-ATG) had secondary graft failure and were successfully transplanted with PBSC of the same donor. One patient had a primary graft failure after a CBT and was successfully transplanted with PBSC from a haploidentical sibling. Four patients with graft failure are alive. Non-myeloablative conditioning containing Fludarabine, resulted in less hospital stay compared to Cy-ATG and Cy alone (22.9, 32, 33 days respectively), less fever (1.7, 6.7, 7 days), less parenteral nutrition (0.1, 9, 4 days) and less red cells (2.4, 3.8, 3.8) and platelet (4.5, 7.5, 9.75) transfusions. The median follow-up was 18.4 months (range: 4.3- 45.3). Five-year overall survival (OS) was 70.5%; 94% for Flu-Cy-ATG; 75% for Cy-ATG and 30% Cy (p = 0.0008). There was no significant difference in survival related to age (less than 40 years (n = 53) 73,3% vs over 40 years (n = 15) 69.9%, p = 0.67). There as superior survival for transplants performed before 2004 (n = 18) compared with those after (n = 50) (51% vs 78%, p = 0.38). This experience shows excellent survival for Allo-SCT in patients with BMFS regardless the age, demonstrating advantage of Flu based RIC over other conditioning regimens.